The median duration of response was 5.8 months (8.8 months for CR patients) with OS of 9.3 months (19.7 in patients with CR) and a 1-year survival was estimated to be 39% (NCT01915498).49,202 Overall, treatment was well tolerated and these studies have led to enasidenib being the first IDH2 mutant inhibitor to be FDA approved for the use in R/R IDH2-mutated AML.203 Currently, there is a randomized, open-label, phase III clinical trial comparing enasidenib vs conventional therapeutic regimens in older patients (≥60 years) with R/R IDH2-mutated AML following failed treatments (NCT02577406). This evidence concerns the gene IDH2 and acute myeloid leukemia.